Head-To-Head Contrast: Century Therapeutics (NASDAQ:IPSC) versus Omega Therapeutics (NASDAQ:OMGA)

Omega Therapeutics (NASDAQ:OMGA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares Omega Therapeutics and Century Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omega Therapeutics	$8.10 million	0.85	-$97.43 million	($1.33)	-0.09
Century Therapeutics	$6.59 million	5.33	-$136.67 million	($1.63)	-0.25

Omega Therapeutics has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Omega Therapeutics and Century Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omega Therapeutics	0	1	4	0	2.80
Century Therapeutics	0	0	5	0	3.00

Omega Therapeutics presently has a consensus price target of $9.20, indicating a potential upside of 7,260.00%. Century Therapeutics has a consensus price target of $4.40, indicating a potential upside of 978.96%. Given Omega Therapeutics’ higher possible upside, equities analysts plainly believe Omega Therapeutics is more favorable than Century Therapeutics.

Profitability

This table compares Omega Therapeutics and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omega Therapeutics	-902.93%	-213.13%	-41.24%
Century Therapeutics	-4,837.73%	-61.66%	-31.78%

Insider & Institutional Ownership

97.5% of Omega Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 8.5% of Omega Therapeutics shares are held by company insiders. Comparatively, 6.8% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Omega Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.

Summary

Omega Therapeutics beats Century Therapeutics on 8 of the 14 factors compared between the two stocks.

About Omega Therapeutics

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.